ArticleMolecular and cellular biochemistry2026
Therapeutic potential of umbilical cord-derived mesenchymal stem/stromal cells versus their conditioned media on treatment of polycystic ovary In-vivo.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine and reproductive disorder affecting females of reproductive age. This study explored the therapeutic potential of umbilical cord-derived mesenchymal stem cells (UC-derived MSCs) and their conditioned medium (UC-derived MSCs-CM) in a letrozole-induced PCOS rat model (n = 8 per group; four groups: control, PCOS, MSC-treated, and MSC-CM-treated). An additional subset (n = 5 per group) was used for mating studies. Various assessments were carried out, including fertility outcomes, monitoring of the estrous cycle, hormonal profiling (including testosterone, luteinizing hormone [LH], follicle-stimulating hormone [FSH], LH/FSH ratio, progesterone, estrogen, and insulin), insulin resistance index (HOMA-IR), lipid metabolism parameters (cholesterol, triglycerides, low-density lipoprotein [LDL], and high-density lipoprotein [HDL]), oxidative stress biomarkers (glutathione and malondialdehyde [MDA]), and markers of apoptosis (Annexin V/PI and Caspase-3). Histological and immunohistochemical analyses of ovarian and uterine tissues were also completed. Data were analyzed using one-way ANOVA with Tukey's post hoc test for most parameters, the Kruskal-Wallis test with Dunn's post hoc test for non-normally distributed variables, and Fisher's exact test for pregnancy rates. Results are presented as mean ± SD, and significance was set at p < 0.05. Inducing PCOS led to reproductive and metabolic problems, including high androgen levels, increased insulin levels, elevated HOMA-IR, abnormal lipid levels, heightened oxidative stress, increased apoptotic activity, and raised proinflammatory cytokine levels. Both UC-derived MSCs and UC-derived MSCs-CM treatments significantly enhanced these issues by reducing oxidative stress, lowering apoptotic and inflammatory markers, and balancing reproductive hormones. Remarkably, UC-derived MSCs treatment has shown stronger effects, restoring normal estrous cycles, improving ovarian structure, and resulting in positive pregnancy outcomes. These findings suggest that UC-derived MSCs could be a promising cell-based treatment for PCOS and that UC-derived MSCs-CM might be a safe, cell-free alternative with significant therapeutic potential.
Indexed as
Identifiers
41557127What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.